Summary: The European competent authorities for medicinal products have just approved ALK's new adrenaline pen, JEXT®, for emergency treatment of severe acute allergic reactions. In the months ahead, ALK expects to launch JEXT® on the first European markets as a substitute for the company's existing inlicensed product. As announced on 7 October 2010, ALK has developed a new and improved adrenaline auto-injector called JEXT®. The competent authorities for medicinal products in 17 European countries have just approved JEXT® for the emergency treatment of severe acute allergic reactions (anaphylaxis) caused by, for example, foods or bee stings. The approval has been obtained by means of the European authorities' Decentralised Procedure. Following this approval, the national authorities will issue formal marketing authorisations. This is expected to happen in the near future. JEXT® is expected to be available on the first European markets on 1 January 2011. ALK holds the global product rights and is planning to expand its geographical presence with adrenaline products considerably. Furthermore, with the introduction of JEXT®, ALK expects to improve the company's gross margin and substantially improve earnings from the business area within the next few years. ALK-Abelló A/S Jens Bager President and CEO Contact: Jens Bager, President and CEO, tel. (+45) 4574 7576 Investor Relations: Per Plotnikof, tel. (+45) 4574 7527, mobile (+45) 2261 2525 Press: Martin Barlebo, tel. (+45) 4574 7901, mobile (+45) 2064 1143